JOHNSON & JOHNSON (JNJ)

↓ Download CSV

CIK 0000200406 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated NJ
  • Fiscal year ends Jan 3

In fiscal 2025, JOHNSON & JOHNSON reported revenue of $94.19B, up 6.0% from the prior year. The company was profitable, with a net margin of 28.5% and a gross margin of 67.9%. It held $199.21B in total assets against $117.67B in total liabilities.

Key ratios (FY2025)

67.9%
Gross margin
28.5%
Net margin
32.9%
Return on equity
+6.0%
Revenue growth (YoY)
Metric (FY)2025202420232022202120192018201720162014
Revenue$94.19B$88.82B$85.16B$78.74B$82.58B$82.06B$81.58B$76.45B
Cost of Revenue$30.26B$27.47B$26.55B$23.40B$28.43B$27.56B$27.09B$25.44B
Gross Profit$63.94B$61.35B$58.61B$55.34B$54.16B$54.50B$54.49B$51.01B$48.54B$51.59B
Operating Income$21.59B
Net Income$26.80B$14.07B$35.15B$20.88B$14.71B$15.12B$15.30B$1.30B$15.41B$16.32B
EPS (Diluted)$11.03$5.79$13.72$7.81$5.51$5.63$5.61$0.47$5.48$5.70
Total Assets$199.21B$180.10B$167.56B$182.02B$174.89B$157.73B$152.95B$157.30B$133.41B$130.36B
Total Liabilities$117.67B$108.61B$98.78B$108.00B$111.62B$98.26B$93.20B$97.14B$62.26B$60.61B
Shareholders' Equity$81.54B$71.49B$68.77B$74.02B$63.28B$59.47B$59.75B$60.16B$71.15B$69.75B
Cash & Equivalents$19.71B$24.11B$21.86B$14.49B$13.98B$17.30B$18.11B$17.82B$13.73B$14.52B
Operating Cash Flow$24.53B$24.27B$22.79B$23.41B$23.54B$23.42B$22.20B$21.06B$19.57B$18.71B
Capital Expenditures$4.83B$4.42B$4.54B$3.65B$3.35B$3.50B$3.67B$3.28B$3.46B$3.71B
Shares Outstanding2.43B2.43B2.56B2.67B2.67B2.68B2.73B2.75B2.81B2.86B
Dividends Per Share$5.14$4.91$4.70$4.19$3.98$3.75$3.54$3.32$2.95$2.76